+85.6%
IREN vs GSK
+40.9%
+44.7%
-95.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.3% | +0.2% | -3.5% | -3.3% |
| 7D | +14.6% | -3.6% | +18.2% | +13.4% |
| 30D | +17.1% | -5.9% | +23.0% | +15.3% |
| 3M | -16.0% | -4.3% | -11.8% | -16.5% |
| 6M | +16.8% | -10.8% | +27.6% | +14.3% |
| YTD | +20.1% | +1.8% | +18.3% | +22.1% |
| 1Y | +50.3% | +23.5% | +26.8% | +58.3% |
| 3Y | +871.5% | +49.5% | +822.0% | +959.5% |
| All | +85.6% | +40.9% | +44.7% | +68.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling